http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 16:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+Miljkovic+Milos/26591635.html si-local-file:///var/storage/secattach/20260602/26591635.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+Miljkovic+Milos/26591635.html Tue, 02 Jun 2026 16:07:00 -0400 O.04856707 RNAC http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+Miljkovic+Milos/26591635.html si-local-file:///var/storage/secattach/20260602/26591635.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+Miljkovic+Milos/26591635.html Tue, 02 Jun 2026 16:07:00 -0400 O.04856707 RNAC http://www.streetinsider.com/Analyst+Comments/Mizuho+on+Cartesian+Therapeutics+%28RNAC%29%3A+%27We+believe+the+potential+of+Descartes-08+remains+underappreciated%27/26547598.html <p>Mizuho analyst Uy Ear reiterated an Outperform rating and $40.00 price target on Cartesian Therapeutics (NASDAQ: RNAC).</p><p>The analyst comments "This morning, Cartesian announced that it has secured a non-dilutive credit facility of up to $150M with K2 HealthVentures. Cartesian's initial $50M draw extends its cash runway from mid-2027 into 2028 and provide funding for pre-commercial activities for Descartes-08 in myasthenia gravis. Additionally, Cartesian provided its mid-year update, moving up the top-line readout timeline for its registrational Phase 3 AURORA trial in myasthenia gravis from mid-2027 to 1Q27 -- suggesting that enrollment is likely near completion -- and expecting potential BLA http://www.streetinsider.com/Analyst+Comments/Mizuho+on+Cartesian+Therapeutics+%28RNAC%29%3A+%27We+believe+the+potential+of+Descartes-08+remains+underappreciated%27/26547598.html Tue, 26 May 2026 10:48:12 -0400 RNAC http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cartesian+Therapeutics%2C+++For%3A+May+22/26545773.html si-local-file:///var/storage/secattach/20260526/26545773.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cartesian+Therapeutics%2C+++For%3A+May+22/26545773.html Tue, 26 May 2026 07:09:00 -0400 O.04856707 RNAC http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cartesian+Therapeutics%2C+++For%3A+May+22/26545773.html si-local-file:///var/storage/secattach/20260526/26545773.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cartesian+Therapeutics%2C+++For%3A+May+22/26545773.html Tue, 26 May 2026 07:09:00 -0400 O.04856707 RNAC http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html <p>Cartesian Therapeutics Inc. (NASDAQ: RNAC) announced it has secured a credit facility of up to $150 million from K2 HealthVentures LLC, with an initial $50 million tranche funded upon signing. The biotechnology company expects this financing to extend its cash runway into 2028 and support advancement of clinical programs for its cell therapy candidate Descartes-08.</p> <p>The company anticipates topline data from its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis in the first quarter of 2027, with a biologics license application filing planned for mid-2027. Additional data readouts are expected in the first half of 2027 from the Phase 2 http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html Tue, 26 May 2026 07:00:32 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html <p>Cartesian Therapeutics Inc. (NASDAQ: RNAC) announced it has secured a credit facility of up to $150 million from K2 HealthVentures LLC, with an initial $50 million tranche funded upon signing. The biotechnology company expects this financing to extend its cash runway into 2028 and support advancement of clinical programs for its cell therapy candidate Descartes-08.</p> <p>The company anticipates topline data from its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis in the first quarter of 2027, with a biologics license application filing planned for mid-2027. Additional data readouts are expected in the first half of 2027 from the Phase 2 http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html Tue, 26 May 2026 07:00:32 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html <p>Cartesian Therapeutics Inc. (NASDAQ: RNAC) announced it has secured a credit facility of up to $150 million from K2 HealthVentures LLC, with an initial $50 million tranche funded upon signing. The biotechnology company expects this financing to extend its cash runway into 2028 and support advancement of clinical programs for its cell therapy candidate Descartes-08.</p> <p>The company anticipates topline data from its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis in the first quarter of 2027, with a biologics license application filing planned for mid-2027. Additional data readouts are expected in the first half of 2027 from the Phase 2 http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html Tue, 26 May 2026 07:00:32 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html <p>Cartesian Therapeutics Inc. (NASDAQ: RNAC) announced it has secured a credit facility of up to $150 million from K2 HealthVentures LLC, with an initial $50 million tranche funded upon signing. The biotechnology company expects this financing to extend its cash runway into 2028 and support advancement of clinical programs for its cell therapy candidate Descartes-08.</p> <p>The company anticipates topline data from its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis in the first quarter of 2027, with a biologics license application filing planned for mid-2027. Additional data readouts are expected in the first half of 2027 from the Phase 2 http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html Tue, 26 May 2026 07:00:32 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html <p>Cartesian Therapeutics Inc. (NASDAQ: RNAC) announced it has secured a credit facility of up to $150 million from K2 HealthVentures LLC, with an initial $50 million tranche funded upon signing. The biotechnology company expects this financing to extend its cash runway into 2028 and support advancement of clinical programs for its cell therapy candidate Descartes-08.</p> <p>The company anticipates topline data from its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis in the first quarter of 2027, with a biologics license application filing planned for mid-2027. Additional data readouts are expected in the first half of 2027 from the Phase 2 http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html Tue, 26 May 2026 07:00:32 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html <p>Cartesian Therapeutics Inc. (NASDAQ: RNAC) announced it has secured a credit facility of up to $150 million from K2 HealthVentures LLC, with an initial $50 million tranche funded upon signing. The biotechnology company expects this financing to extend its cash runway into 2028 and support advancement of clinical programs for its cell therapy candidate Descartes-08.</p> <p>The company anticipates topline data from its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis in the first quarter of 2027, with a biologics license application filing planned for mid-2027. Additional data readouts are expected in the first half of 2027 from the Phase 2 http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html Tue, 26 May 2026 07:00:32 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html <p>Cartesian Therapeutics Inc. (NASDAQ: RNAC) announced it has secured a credit facility of up to $150 million from K2 HealthVentures LLC, with an initial $50 million tranche funded upon signing. The biotechnology company expects this financing to extend its cash runway into 2028 and support advancement of clinical programs for its cell therapy candidate Descartes-08.</p> <p>The company anticipates topline data from its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis in the first quarter of 2027, with a biologics license application filing planned for mid-2027. Additional data readouts are expected in the first half of 2027 from the Phase 2 http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html Tue, 26 May 2026 07:00:32 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html <p>Cartesian Therapeutics Inc. (NASDAQ: RNAC) announced it has secured a credit facility of up to $150 million from K2 HealthVentures LLC, with an initial $50 million tranche funded upon signing. The biotechnology company expects this financing to extend its cash runway into 2028 and support advancement of clinical programs for its cell therapy candidate Descartes-08.</p> <p>The company anticipates topline data from its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis in the first quarter of 2027, with a biologics license application filing planned for mid-2027. Additional data readouts are expected in the first half of 2027 from the Phase 2 http://www.streetinsider.com/FDA/Cartesian+Therapeutics+secures+%24150+million+credit+facility+from+K2+HealthVentures/26545673.html Tue, 26 May 2026 07:00:32 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html <p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028</em></p> <p align="center"><em>Financing strengthens Cartesian’s financial flexibility, further supporting advancement of multiple clinical programs to data read out including myasthenia gravis and myositis, while also accelerating pre-launch activities</em></p> <p align="center"><em>Topline data from Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027</em></p> <p align="center"><em>Data from subset of patients in Phase 2 TRITON trial of Descartes-08 in myositis expected in 1H27</em></p> <p align="center"><em>Data from Phase 1/2 HELIOS http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Secures+up+to+%24150+Million+of+Non-Dilutive+Financing+from+K2+HealthVentures+and+Expects+Topline+Data+from+the+Phase+3+AURORA+Trial+in+First+Quarter+2027/26545624.html Tue, 26 May 2026 07:00:00 -0400 A.06822034 A.07435818 A.40866182 O.04856707 O.05851094 O.20026344 O.47796754 RNAC